The Lancet. Respiratory medicine
Treatment for severe acute respiratory distress syndrome from COVID-19.
Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials.
Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.
A new frontier in ARDS trials: phenotyping before randomisation.
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.
Precision medicine for cell therapy in acute respiratory distress syndrome - Authors' reply.
Screening for tuberculosis: time to move beyond symptoms.
ECMO in severe acute respiratory distress syndrome.
Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial.
